TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05114590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide
Description: Solution for injection in a pre-filled pen by subcutaneous injection. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.
Study: NCT05552053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MWSH plus Candlelit Care
Description: Candlelit Care is a virtual perinatal mental health application that builds on cognitive behavioral therapy (CBT) to provide Black, Indigenous and POC women and birthing parents access to culturally affirming mental health support during pregnancy. Driven by an integrated care team, women have access to self-guided therapeutic tools, peer coaching and education about perinatal mood disorders as a primary resource. This convenient and trauma informed app allows parents to see if their mental health symptoms warrant further treatment in a secure setting. The app also provides education of role transitions, discussion of types of interpersonal conflicts common around childbirth (including racial discrimination) and techniques for resolving them, and role-playing with feedback from other parents during groups. The goals are to improve self-advocacy skills; patient communication with medical providers and provide a support network with other Black pregnant women.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MWSH
Description: The Maternal Wellness Self Help (MWSH) app was created to help individuals to manage perinatal depression and anxiety. The app is designed is to meet the emotional needs of those who are pregnant, want to become pregnant or have given birth. This psycho-educational app informs and normalizes the range of emotional responses throughout the reproductive journey. By learning about perinatal mental health, this app hopes to empower patients to understand and name their experiences.
Study: NCT05564299

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid 30-minute Desktop Assay
Description: Participants will undergo routine evaluation and specimen collection per current clinic protocols. Specimens will be processed by the rapid 30-minute desktop assay. Concurrently, specimens will be used to create a point-of-care gram stain, to be read by the clinician following the clinical encounter.~Treatment for urethritis and cervicitis will be provided based on results from the 30-minute assay.~Specimens will also be plated for Gonorrhea culture and sent to the Massachusetts Department of Public Health for additional Gonorrhea and Chlamydia polymerase chain reaction testing, as per clinic protocols.
Study: NCT05791461

Intervention type: BEHAVIORAL
Intervention: MARS (Measures Against Work-related Stress)
Description: The stress management intervention is based on cognitive behavioral therapy and aims to change the way patients perceive and cope with stressful situations at work.~It is group sessions over 3 months with approximately 9 participants. Participants meet 9 times (once a week the first 3 weeks and once every second week the last 5 times) and for a follow-up session 3 months after the intervention has ended. Each session lasts for 3 hours and is led by a trained psychologist. The participants perform tasks at home between the sessions. In the first session the rationale behind the intervention is introduced. In session 2 and 3 the patients work with enhancing self-regulation. In session 4 and 5 the focus is on modifying intermediate beliefs. In session 6 the focus is on improving interaction. Session 7 and 8 focuses on consolidation of learning and strategies to prevent relapse, and session 9 is a follow-up session 3 months after the intervention has ended.
Study: NCT04713046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16
Description: Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10\^6 CD4+ cells/kg; 2) 5 x 10\^6 CD4+ cells/kg; or 3) 10\^7 CD4+ cells/kg of recipient ideal body weight.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16
Description: Standard dosing for bone marrow graft (target dose of 4 x 10\^8 nucleated cells/kg) and if progression at Day 90, will receive dose level 1 for the CD8-depleted DLI (106 CD4+ cell/kg).
Study: NCT06537401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypercaloric, High Fat Diet
Description: Participants will select meals from a list of sample breakfast, lunch, and dinner options from grocery stores. Typical intake will be estimated as 160-170% of resting metabolic rate, which will then be multiplied by 1.65 as the target calorie intake for the HFD. Target fat intake will be 65% of the HFD calorie target. To ensure participants will achieve the desired calorie and fat intake, they will also be provided with pre-made nutrient shakes and half-and-half. Participants will supplement their food intake with one to three shakes per day for each of the three days, depending on the fat and calorie content of the foods they select. They will be asked to add half-and-half equally between across the shakes.
Study: NCT06339996

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Male supplement
Description: Participants will be administered supplements for a three-month treatment period
Study: NCT05760118

Intervention type: OTHER
Intervention: Patient Participation Form
Description: A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
Study: NCT05160987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
Study: NCT06302738

Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: patients will undergo a home sleep study to evaluate the presence of sleep disorders
Study: NCT04735718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerviron
Description: Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.~Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations.
Study: NCT04750408

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen
Description: COT describes the application of low-flow oxygen in any way (Hudson mask, nasal prongs,...).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high-flow
Description: F is combination of room air supplemented with oxygen can be better patients. This gas mixture will be provided to the patient with a specialized nasal prong.
Study: NCT06021119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl peptidase-4 inhibitors
Description: Dipeptidyl peptidase-4 inhibitors with Iftar meal
Study: NCT05126758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAP-1002
Description: Cohort A: CAP-1002A manufactured in Los Angeles, CA; Cohort B: CAP-1002B manufactured in San Diego, CA

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04858789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)
Description: CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This transdiagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase well-being by targeting cognitive and behavioral changes.
Study: NCT01141790

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Music and voice message
Study: NCT06500702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: frexalimab
Description: frexalimab treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442970
Description: SAR442970 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilzabrutinib
Description: rilzabrutinib treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo treatment
Study: NCT05267834

Intervention type: PROCEDURE
Intervention: Conization and/or Hysterectomy
Description: Women undergoing cervical conization or simple/modified/radical hysterectomy with or without pelvic lymphadenectomy

Intervention type: PROCEDURE
Intervention: Conization and/or Hysterectomy
Description: Women undergoing cervical conization or simple/modified/radical hysterectomy with or without pelvic lymphadenectomy
Study: NCT06199505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR101
Description: Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degledec/insulin aspart
Description: Once daily or twice daily
Study: NCT05812131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPEWeb online training
Description: COPE training delivered via online COPEWEb to providers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COPE In Person
Description: COPE training provided in person to providers
Study: NCT06564207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be given twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib 150mg to be given twice daily for 14 days
Study: NCT06653725

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1,3-butanediol
Description: 1,3-butanediol (Ketone-IQ®) 118 mL (33 g) servings trice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taste-matched placebo (isovolumic, isoviscous water with stevia) 118 mL servings trice daily
Study: NCT05951179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TARA-002
Description: All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 21 until Month 60.
Study: NCT06653530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thread embedding acupuncture
Description: Thread embedding acupuncture is performed using polyglycolic acido thread. Needles have a gauge size of 23G, a shaft length of 60mm, and a thread length of 50mm, folded in half, and are applied to fourteen acupoints, including Zhongwan (CV12), Qihai (CV6), bilateral Tianshu (ST 25), bilateral Wailing (ST 26), bilateral Daheng (SP 15), bilateral Zusanli (ST 36), bilateral Pishu (BL 20), and bilateral Weishu (BL 21). After the thread is inserted into the body, the needle will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham thread embedding acupuncture
Description: The protocol includes the same duration and frequency of sessions as for thread embedding acupuncture, but the treatment will be delivered superficially at non-acupuncture points 10mm from the lateral of the corresponding acupuncture and not above a meridian line. Needles without threads have a gauge size of 23G, and a shaft length of 60mm will be used. After the needle is inserted into the body, it will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
Study: NCT05573113

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bowel Ultrasound
Description: Bowel Ultrasound

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal radiograph
Description: Abdominal radiograph

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal radiograph
Description: Abdominal radiograph
Study: NCT06603246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-6988
Description: GDC-6988 will be administered using a dry powder inhalation
Study: NCT06444594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPM8 Agonist
Description: menthol gel 4-10%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV1 Agonist
Description: camphor gel 5-20%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV4 Agonist
Description: capsaicin gel 0.05-1%%
Study: NCT05485350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: 12 mg/d, d1-14, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: penpulimab
Description: 200mg, ivgtt, d1, q3w
Study: NCT06444594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPM8, TRPV4, TRPV1 Agonists
Description: menthol (4-10%), capsaicin (0.05-1%), camphor (5-20%)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Inactive vehicle gel
Study: NCT06665477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Volyme
Description: Subjects in Restylane Volyme treatment group will receive treatment on Day 1 and optiponal treatment 1 month later.
Study: NCT05570734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LUNA Care Coordination
Description: Participants in this group will have 6 or more 30-minute care coordination sessions with the LUNA Care Coordinator. The LUNA Care Coordinator will assist with appointments and referrals, medications, and assist with accessing the health education videos. They will work closely with the participant's primary care provider and the LUNA Behavioral Health Provider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LUNA Behavioral Health
Description: Participants in this group will have 6 or more 30-minute behavioral health sessions with the LUNA Behavioral Health Provider. The LUNA Behavioral Health Provider will screen and address life stressors, social support, and health care use. The purpose of these sessions is to check on participant's progress with their care plan. The behavioral health sessions will involve discussion of issues that may interfere with optimal diabetes self-management. The LUNA Behavioral Health Provider will help participants overcome any potential barriers to managing their diabetes by setting goals and helping to address life stress or other issues that may be interfering with their diabetes self-management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Videos
Description: Participants in this group will have access to eight 20 to 30-minute health education video sessions with corresponding print material and activities to reinforce what they learn. The health education videos focus on medication adherence, self-monitoring, stress and coping, nutrition, physical activity and culturally driven beliefs and values.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Integrated Visits
Description: Participants in this group will have two virtual integrated visits with the LUNA care team. Through video conferencing, they will meet at the same time with the LUNA Care Coordinator, the LUNA Behavioral Health Provider, and their primary care provider to ensure an integrated care plan.
Study: NCT06613659

Intervention type: DRUG
Intervention: traditional Chinese medicine (TCM)
Description: Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.

Intervention type: DRUG
Intervention: non traditional Chinese medicine (non-TCM)
Description: Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposed group used TCM syndrome differentiation therapy combined with conventional western medicine treatment (integrative medicine treatment cohort), and the non exposed group used conventional western medicine treatment without standardized TCM syndrome differentiation treatment (Western medicine treatment cohort). The treatment plan was formulated by the clinician, and the researcher did not intervene.
Study: NCT06615375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella4V2
Description: Shigella4V2 is a tetravalent bioconjugate vaccine which consists of the O-antigen polysaccharide of Shigella flexneri 2a, 3a, 6 and of S. sonnei, conjugated to the detoxified Pseudomonas aeruginosa exotoxin A protein as carrier protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella4V2
Description: Shigella4V2 is a tetravalent bioconjugate vaccine which consists of the O-antigen polysaccharide of Shigella flexneri 2a, 3a, 6 and of S. sonnei, conjugated to the detoxified Pseudomonas aeruginosa exotoxin A protein as carrier protein.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate-buffered saline
Study: NCT06730672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volonib combined with Everolimus Formation
Description: Volonib 200mg once daily and Everolimus 5mg once daily
Study: NCT06729801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRP-Monitoring Flexible and Navigable Suction Ureteral Access Sheath (FANS)
Description: The IRP-Monitoring Flexible and Navigable Suction Ureteral Access Sheath (FANS) is a novel device designed to enable real-time monitoring of intrarenal pressure (IRP) during retrograde intrarenal surgery (RIRS). It incorporates a pressure-sensing port connected to a gas conduit embedded in the sheath, which allows the surgeon to adjust irrigation flow and suction pressure based on real-time IRP readings, thereby optimizing stone retrieval efficiency while ensuring safety by maintaining a safe IRP range. The device improves surgical outcomes, particularly in complex cases involving larger renal stones, by reducing operative time and minimizing the risk of complications.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional FANS
Description: The Conventional Flexible and Navigable Suction Ureteral Access Sheath (FANS) is a standard device used in retrograde intrarenal surgery (RIRS) for stone retrieval. Unlike the IRP-monitoring version, this device does not provide real-time monitoring of intrarenal pressure (IRP). Irrigation flow and suction pressure are pre-set and adjusted based on clinical protocols. It facilitates the removal of renal stones through a flexible and navigable design, but without the added capability of monitoring and adjusting IRP during the procedure.
Study: NCT06725030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symani Surgical System
Description: The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
Study: NCT06739382

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin.
Description: In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin in group (A) of patients.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: two β-lactam antibiotics plus a single non-β-lactam antibiotic
Description: In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to include two β-lactam antibiotics plus a single non-β-lactam antibiotic, or a combination of double β-lactam antibiotics, with the aim of avoiding aggressive and toxic antibiotics in group (B) of patients

Intervention type: OTHER
Group type: OTHER
Intervention: Control group received standard therapy
Description: Treatment was adjusted to the second-line empirical antibiotic according to the hospital's local policy.
Study: NCT06736041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV21 vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 20 vaccine
Description: Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Study: NCT05485350

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 55-180Gy